Filing identity and reporting period
Material metadata mismatch: The supplied filing is Kintara Therapeutics, Inc.’s Form 10-Q, not a filing by TuHURA Biosciences, Inc. It covers the quarter and nine months ended March 31, 2024—not 2023 Q3. Financial amounts below are in U.S. dollars, in thousands, unless stated otherwise.
Business context
Kintara is a clinical-stage oncology company with no revenue to date. Its focus is REM-001, a photodynamic therapy candidate for cutaneous metastatic breast cancer (CMBC). It terminated development of VAL-083 after preliminary glioblastoma results did not outperform current standards of care, and assigned VAL-083 patent rights to Valent in February 2024.
Financial performance and liquidity
| Metric | Quarter ended Mar. 31, 2024 | Nine months ended Mar. 31, 2024 | Comparable 2023 period |
|---|---|---|---|
| Revenue | None | None | None |
| Research and development | $592 | $2,562 | $2,005; $7,235 |
| General and administrative | $1,493 | $3,504 | $1,297; $4,212 |
| Net loss | $(2,011) | $(5,996) | $(3,264); $(11,314) |
| Loss per share | $(0.05) | $(0.37) | $(1.94); $(7.32) |
| Cash used in operating activities | Not stated | $(5,734) | $(10,357) |
Quarterly and nine-month R&D expenses fell 70% and 65%, respectively, year over year, mainly reflecting lower clinical costs and share-based compensation. Quarterly G&A rose 15%, including higher professional fees related to the proposed TuHURA transaction; nine-month G&A fell 17%. The company reported no operating revenue, so revenue margins are not applicable.
At March 31, 2024, cash and cash equivalents were $6,351, current assets $6,755, current liabilities $1,341, and working capital $5,414. Total liabilities were $1,524, including a $183 milestone payment liability; the filing reports no conventional borrowings. Cash increased by $4,816 during the nine months, chiefly because of equity financing: financing cash inflow was $10,570. No cash runway estimate is provided.
Changes, outlook, and key risks
- Net loss narrowed from $11,314 to $5,996 for the nine-month comparison, while operating cash use fell from $10,357 to $5,734.
- Kintara raised $10,471 net through its ATM facility and $105 through its Lincoln Park equity facility during the nine months. It issued 53,151 thousand ATM shares at a weighted average price of $0.21; both facilities were concluded by February 22, 2024. Common shares outstanding increased to 55,305 thousand from 1,692 thousand at June 30, 2023.
- A $2,000 NIH grant supports REM-001; $404 had been received in the nine months. As of May 14, 2024, two patients had started treatment in the 15-patient study. Management expected enrollment completion in calendar Q3 2024. The grant is conditional and reimburses eligible costs.
- Management stated that substantial doubt exists about the company’s ability to continue as a going concern within one year of the filing. It expects to need significant additional funding; financing may not be available, and the company warned it could reduce or stop programs, face insolvency, or be delisted if financing or the merger does not proceed.
- On April 2, 2024, Kintara agreed to merge with TuHURA, subject to stockholder and regulatory approval, with closing expected in calendar Q3 2024. Existing Kintara holders were expected to own approximately 2.85% of the combined company, or 5.45% including contingent value rights tied to REM-001 enrollment and follow-up milestones. Certain termination scenarios require a $1,000 fee, and one scenario also provides for expense reimbursement up to $750.
- Nasdaq had notified Kintara of minimum-bid-price noncompliance, with a June 10, 2024 deadline to regain compliance. Kintara separately reported it had regained compliance with the minimum stockholders’ equity requirement. Series C preferred shares were scheduled to convert automatically on August 19, 2024; the filing estimates a further 59 thousand dividend shares for that preferred class.
- Subsequent compensation approvals included a $327 one-time CEO bonus and $93 of accrued director fees. The filing reports no legal proceedings and no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the issuer and reporting period: this is Kintara’s March 31, 2024 Form 10-Q, despite the request identifying TuHURA and 2023 Q3.
- Check the status and final terms of the proposed merger, required approvals, expected ownership split, contingent value rights, and any termination payments.
- Verify current cash, subsequent financing, and management’s assessment of funding needs and going-concern risk.
- Check REM-001 enrollment, grant reimbursements and conditions, clinical results, and whether the projected enrollment timeline was achieved.
- Assess dilution and capital structure, including the ATM issuance, preferred conversions and dividends, warrants, options, and post-merger ownership.
- Confirm Nasdaq bid-price compliance and continued listing status after the stated deadline.